GHK-Cu

No controlled human study of GHK-Cu is cited here that can be read first hand. The human skin results that get quoted for it arrive secondhand, summarized in two reviews written by the scientist who discovered the molecule and a colleague, both working from a skin-care research company. The original trial reports are not among the sources.

The reason GHK-Cu gets attention anyway is solid biology at the bench. GHK is a three-amino-acid fragment the body makes on its own, it binds copper tightly, and in fibroblast cultures and in a rat wound model the copper complex pushed tissue toward making more collagen and connective matrix. Those are the best direct findings available, and none of them involved a living person.

It is also one of the most familiar names in skin care, which is part of the problem. A cream ingredient sold for decades feels tested. Familiarity and controlled evidence are different things, and for GHK-Cu the gap between them is wide.

GHK-Cu is glycyl-L-histidyl-L-lysine, a tripeptide, held in a complex with a copper ion. GHK occurs naturally in human plasma, saliva and urine. One review puts plasma levels at about 200 ng/mL at age 20, falling to about 80 ng/mL by age 60. That is a measurement of the body's own peptide. It says nothing about what adding more from outside does.

The sequence also sits inside type I collagen itself, in the alpha 2(I) chain. The original fibroblast paper proposed that proteases at a wound could cut it loose, so the tissue being repaired would release its own repair signal. That is a hypothesis about how the molecule fits into normal healing, not a demonstrated pathway in people.

Its grip on copper is close to albumin's. The 2015 review gives a binding constant of log10 16.44 for GHK against 16.2 for albumin's high-affinity copper site, which is why GHK can pull copper off albumin in solution.

What the Fibroblast and Rat Work Actually Showed

In 1988, Maquart and colleagues added GHK-Cu to fibroblast cultures and measured collagen synthesis. The effect started at concentrations between about 1 and 10 picomolar and peaked at 1 nanomolar, and it did not depend on the cells multiplying. More collagen per cell, not more cells.

The 1993 follow-up moved to rats. Stainless steel mesh cylinders were implanted under the skin of the back, and GHK-Cu or saline was injected straight into those wound chambers. GHK-Cu produced a concentration-dependent rise in dry weight, DNA, total protein, collagen and glycosaminoglycans. Collagen synthesis rose twice as much as non-collagen protein, type I and type III collagen mRNA went up, and TGF beta mRNA did not. A control tripeptide had no significant effect, which is the detail that makes the result more than noise.

Building and Breaking Down

The reviews describe GHK as stimulating both the synthesis and the breakdown of collagen and glycosaminoglycans, and as modulating both matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2. If that holds, the molecule acts more like a remodeling signal than a collagen accelerator. That framing comes from cell work summarized in the reviews, not from tissue measured in people.

The Gene Data and How Far It Reaches

Much of the bigger talk about GHK-Cu traces to the Broad Institute's Connectivity Map, a public library of how gene expression shifts when cultured cells are exposed to a compound. The 2018 review reports that 31.2 percent of human genes changed by 50 percent or more with GHK, and the 2015 abstract puts it at least 4,000 genes, described as resetting DNA to a healthier state. Those profiles came from cancer cell lines. A change in transcript counts in a dish is a reason to ask questions, and the authors concede as much about their neuron findings: GHK has a significant effect on neurons, they write, but they do not know exactly what it means.

The overreach with GHK-Cu runs along three lines: from cream to injection, from gene counts to rejuvenation, and from the body's own peptide to a supplement.

A cosmetic cream result is not evidence for an injection. Every human result in circulation is topical and cosmetic, and reported secondhand. Injectable GHK-Cu has no human efficacy data in these sources at all. The rat wound-chamber work injected the compound into a chamber of wound fluid, a local experiment, not a systemic one.

Gene counts are not reversed aging. The 4,000-gene figure and the phrase about resetting DNA to a healthier state come from Connectivity Map profiles in cultured cancer cell lines. Moving transcript levels in a dish is a hypothesis generator, and the same reviews extend it to anxiety, pain, cancer and COPD without a human trial behind any of those.

A falling natural level is not a deficiency to top up. Plasma GHK declining from about 200 to about 80 ng/mL between 20 and 60 describes the body's own peptide. No source here shows that supplying GHK-Cu from outside restores anything that decline is supposed to have cost.

The most enthusiastic sources are the closest to the product. Both reviews come from a skin-care company founded around the molecule, and both describe GHK as safe with no adverse effects while presenting no safety data. They also scale rat findings up to human amounts that were never tested. That is advocacy, and it is worth reading as such.

Safety in humans is unknown, for any route. No source here reports adverse event rates, and the reviews' statements that no issues have arisen are assertions without data behind them.

For injection, FDA has published a specific concern: compounded injectable GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and there are limited data in humans to inform safety. The injectable nomination was withdrawn by its nominators on 22 April 2026. That withdrawal took the route off FDA's Category 2 list without resolving the concern, which remains published.

Copper is the other variable. The ex vivo skin study found copper retained in every skin layer it tested, about 438 times baseline in isolated stratum corneum after 48 hours, and its authors argued some of that could become systemically available. The same authors point to the body's tight copper regulation, but how much reaches the body from a given product, and what a product actually contains, is not something any of these sources measured in a living person.

GHK-Cu is worth knowing about because its bench biology is coherent: a copper-binding fragment of collagen that, in fibroblasts and rat wounds, nudged tissue toward building matrix. That is a real reason it ended up in skin care.

What the sources cannot tell you is whether it does anything measurable in your skin, because the human results are summaries of trials whose reports are not available here, written by people with a stake in the answer. They tell you even less about anything beyond the skin. Injection, systemic repair, recovery, longevity, mood, pain and cancer all rest on cell lines, rodents, or gene-expression software.

The sensible reading: a plausible cosmetic ingredient with a thin and secondhand human record, and an injectable form that FDA has flagged and nobody has studied in people.

Not an approved drug. GHK-Cu is not FDA approved for any use. Several copper-containing drugs are approved, including copper IUDs and copper histidinate, but none is a copper peptide and none says anything about GHK-Cu.

Not cleared for compounding by injection. Under the 503A interim policy, GHK-Cu sits in Category 1 only for non-injectable routes; the listing reads “GHK-Cu (except for injectable routes of administration)”. Injectable GHK-Cu is on neither list. The injectable nomination was withdrawn on 22 April 2026, and on 5 May 2026 a nominator clarified that only the injectable route was meant to be withdrawn, so the non-injectable listing was restored. Category 1 is not an approval. FDA has said it intends to consult its advisory committee before the end of February 2027; an intention to consult is not a decision.

Not settled in tested sport. GHK-Cu is not named on the WADA Prohibited List and neither WADA nor USADA has issued a statement on it. Its status is unknown. Injected use could plausibly fall under S0 or the S2 growth-factor wording, while topical cosmetic use may not count as a pharmacological substance at all.

Not a demonstrated treatment for wounds or aging. The wound findings are from rats and cell culture, and the anti-aging findings are cosmetic measures reported secondhand.

I find GHK-Cu genuinely interesting, and I also think it is the compound in this library most protected by its own familiarity. It has been in face creams for decades, so it feels like a known quantity. When I went back to the sources, the human evidence I could actually open was zero papers. Everything else was a review summarizing trials I could not read, written by the people who built a business on the molecule.

That does not make the cosmetic results false. It means I cannot check them, and I am not going to write about them with more confidence than I can verify. The bench work is better: a clean fibroblast result and a rat study with a proper control peptide. That is where my confidence sits.

The line I hold is the route. A cream and an injection are different products with different risks, and FDA has written down its concerns about the injectable one. Nothing in the topical story carries over to a syringe.